Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Malaria is a leading cause of death and illness around the world. Over 200 million cases are reported every year, and more than 400 000 people die. More than 90% of cases are reported in sub-Saharan Africa. Scientists have spent decades searching for an effective vaccine. Hence the recent excitement when Malawi’s government announced it had launched a pilot programme for the world’s first malaria vaccine, RTS,S (also known as Mosquirix©), produced by the pharmaceutical company, GSK. It’s the first vaccine to demonstrate significant reduction in malaria in children. The Conversation Africa’s Ina Skosana asked immunologist Faith Osier about RTS,S.

The Conversation logo

Similar stories

Modelling the Cost-Effectiveness of COVID-19 Vaccination Strategies in Kenya

The KEMRI-Wellcome Trust Research Programme today released the results of its latest modelling on COVID-19 vaccine scale-up within the country. The analysis found that the country’s COVID-19 vaccination campaign can achieve greater value for money if it focuses on the elderly, rather than a strategy that pursues scaling up vaccines to the whole population.

Emelda Okiro awarded Wellcome Senior Research Fellowship

Dr Emelda Okiro has been awarded the prestigious Wellcome Senior Research Fellowship. Emelda’s fellowship is the first African Senior Research Fellowship awarded in the KEMRI-Wellcome Research Programme and among the less than five SRFs awarded to researchers in Africa.

Large African and South Asian research network finds half of deaths among children admitted to hospital happens after discharge

Young children in sub-Saharan Africa and South Asia who become sick or malnourished continue to have a high risk of death in the six months after being hospitalized, according to findings by researchers in the Childhood Acute Illness & Nutrition (CHAIN) Network. Appearing in The Lancet Global Health, the study of 3,101 acutely ill children at nine hospitals in six countries across sub-Saharan Africa and South Asia found that 48% of the 350 deaths recorded occurred within six months after discharge from hospital.

Community and Public Engagement at KWTRP

Monitoring and Evaluation helps us keep track of our public engagement activities and outcomes. KEMRI -Wellcome Trust recently completed a report detailing our experiences and learning.

Potentially life-saving treatment is safe to use for babies with neonatal sepsis

Results from a clinical trial completed in Kenya have determined that a safe dose of the antibiotic, fosfomycin, can be used to treat babies with neonatal sepsis. This is a significant development, as there are very few antibiotics specifically licensed to treat multidrug-resistant infections in babies. This research was lead by Dr Christina Obiero and Professor Jay Berkley.

Cross-species vaccination by Professor George Warimwe

Royal Society 2021 Africa Prize lecture from Professor George Warimwe. More than 70% of emerging infectious diseases (including viruses) are zoonotic, meaning they are acquired from animals, with some causing serious illness and death in humans as well as the animal host. But, what if we could immunise both humans and animals with the same vaccine?